TY - JOUR
T1 - Personalized tamoxifen
T2 - A step closer but miles to go
AU - Bardia, Aditya
AU - Stearns, Vered
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of the CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of the CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals. Clin Cancer Res; 16(17); 4308-10.
AB - Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of the CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of the CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals. Clin Cancer Res; 16(17); 4308-10.
UR - http://www.scopus.com/inward/record.url?scp=77956246159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956246159&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-10-1506
DO - 10.1158/1078-0432.CCR-10-1506
M3 - Comment/debate
C2 - 20651057
AN - SCOPUS:77956246159
SN - 1078-0432
VL - 16
SP - 4308
EP - 4310
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 17
ER -